A clinical trial of genomic landscapes of patients with FLT3mut AML shows that FLT3/DNMT3A/NPM1 genotypes do not affect clinical outcomes and suggest that the differential impact of the FLT3/DNMT3A/NPM1 genotypes on clinical outcomes may be related to cohort size and characteristics (e.g., age distribution, treatment, genotype, variant type and variant allele frequency) [116]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.